Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis.

Head & Neck Pub Date : 2012-11-01 Epub Date: 2011-09-23 DOI:10.1002/hed.21858

Fausto Petrelli, Sandro Barni

{"title":"Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis.","authors":"Fausto Petrelli, Sandro Barni","doi":"10.1002/hed.21858","DOIUrl":null,"url":null,"abstract":"Background: Anti-epidermal growth factor receptor (EGFR) therapies are effective in head and neck carcinoma. A meta-analysis was performed to assess their efficacy and safety in advanced head and neck carcinoma.Methods: Six trials randomizing 2257 patients with recurrent/metastatic head and neck carcinoma for chemotherapy or best supportive care with or without anti-EGFR therapies were identified. The efficacy data included progression-free survival (PFS), overall survival (OS), response rate, and toxicity.Results: The response rate was higher in the experimental arm (p < .0001; relative risk = 1.62). A significant PFS benefit (p < .0001; hazard ratio [HR] = 0.70) favored the anti-EGFR treatment. Survival was significantly increased if trials of monoclonal antibodies were included (p = .004; HR = 0.83). A higher incidence of diarrhea, skin rash, anorexia, and hypomagnesemia was observed.Conclusions: This meta-analysis suggests that in recurrent/metastatic head and neck cancer the addition of anti-EGFR monoclonal antibodies to standard therapy confers a statistically significant improvement in OS, PFS, and overall response rate.","PeriodicalId":501638,"journal":{"name":"Head & Neck","volume":" ","pages":"1657-64"},"PeriodicalIF":0.0000,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hed.21858","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head & Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.21858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/9/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 10

Abstract

Background: Anti-epidermal growth factor receptor (EGFR) therapies are effective in head and neck carcinoma. A meta-analysis was performed to assess their efficacy and safety in advanced head and neck carcinoma.

Methods: Six trials randomizing 2257 patients with recurrent/metastatic head and neck carcinoma for chemotherapy or best supportive care with or without anti-EGFR therapies were identified. The efficacy data included progression-free survival (PFS), overall survival (OS), response rate, and toxicity.

Results: The response rate was higher in the experimental arm (p < .0001; relative risk = 1.62). A significant PFS benefit (p < .0001; hazard ratio [HR] = 0.70) favored the anti-EGFR treatment. Survival was significantly increased if trials of monoclonal antibodies were included (p = .004; HR = 0.83). A higher incidence of diarrhea, skin rash, anorexia, and hypomagnesemia was observed.

Conclusions: This meta-analysis suggests that in recurrent/metastatic head and neck cancer the addition of anti-EGFR monoclonal antibodies to standard therapy confers a statistically significant improvement in OS, PFS, and overall response rate.

查看原文本刊更多论文

抗egfr靶向药物治疗复发性或转移性头颈癌:一项荟萃分析

背景:抗表皮生长因子受体(EGFR)治疗头颈癌有效。进行了一项荟萃分析来评估它们在晚期头颈部癌中的疗效和安全性。方法:六项试验随机选取2257例复发/转移性头颈癌患者，进行化疗或最佳支持治疗，联合或不联合抗egfr治疗。疗效数据包括无进展生存期(PFS)、总生存期(OS)、缓解率和毒性。结果:实验组有效率较高(p < 0.0001;相对危险度= 1.62)。PFS显著获益(p < 0.0001;风险比[HR] = 0.70)倾向于抗egfr治疗。如果纳入单克隆抗体试验，生存率显著提高(p = 0.004;Hr = 0.83)。观察到腹泻、皮疹、厌食和低镁血症的发生率较高。结论:这项荟萃分析表明，在复发/转移性头颈癌中，在标准治疗中加入抗egfr单克隆抗体，在OS、PFS和总缓解率方面具有统计学意义的改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head & Neck

自引率

0.00%

发文量